IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial
We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-α2a, subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients with progressive metastatic renal cell carcinoma. Treatment course...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2001-10, Vol.85 (8), p.1130-1136 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1136 |
|---|---|
| container_issue | 8 |
| container_start_page | 1130 |
| container_title | British journal of cancer |
| container_volume | 85 |
| creator | Atzpodien, J Kirchner, H Illiger, H J Metzner, B Ukena, D Schott, H Funke, P J Gramatzki, M Jürgenson, S von Wandert, T Patzelt, T Reitz, M |
| description | We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-α2a, subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients with progressive metastatic renal cell carcinoma. Treatment courses consisted of interferon-α2a 5 × 10
6
IU m
–2
day 1 weeks 1 + 4; days 1, 3, 5 weeks 2 + 3; 10 × 10
6
IU m
–2
days 1, 3, 5 weeks 5–8; interleukin-2 10 × 10
6
IU m
–2
twice daily days 3–5 weeks 1 + 4; 5 × 10
6
IU m
–2
days 1, 3, 5 weeks 2 + 3; and 5-fluorouracil 1000 mg m
–2
day 1 weeks 5–8. The tamoxifen group received tamoxifen 80 mg twice daily over 8 weeks. Among 41 patients treated with interleukin-2, interferon-α2a and 5-fluorouracil there were 7 complete (17.1%) and 9 partial responders (21.9%), with an overall objective response rate of 39.1% (95% CI, 24.2–55.5). An additional 15 patients (36.6%) were stable throughout therapy. The overall survival was 24 months (range 5–76+). In 37 patients receiving tamoxifen no objective remissions occurred. 13 patients (35.1%) had stable disease and 24 patients (64.9%) showed continued disease progression. The overall survival was 13 months (range 3–73+). In summary, this home-based therapy regimen of interferon-α2a, interleukin-2 and 5-fluorouracil demonstrated significant therapeutic efficacy in patients with progressive renal cell carcinoma when compared to hormonal therapy. © 2001 Cancer Research Campaign
http://www.bjcancer.com |
| doi_str_mv | 10.1054/bjoc.2001.2076 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2375150</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11710825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-cd379b9356b8ce2321ad09dd0a062b428da57fcc214153dc65c3193aabf9a34c3</originalsourceid><addsrcrecordid>eNp1UctuEzEUtRAVTQtblsgblpP6MZ4HCyRUkRIpKhu6tu7YntSRx65spwW-pL_RH-Gb8CgRhQWba1v3PKxzEHpLyZISUV8Mu6CWjBBaRtu8QAsqOKtox9qXaEEIaSvSM3KKzlLalWdPuvYVOqW0paRjYoEe15uKYeuxCtNgPWQbPH6w-RavV9fVryfwGotqdYPvTUz7hDNM4bsdjZ85k8mQcuEoHI0Hh5VxZUBU1ocJPmAX_LbKJk5ln_YuJxxGDMXL5xicMxrHYhAm-7NclbPeqqKSowX3Gp2M4JJ5czzP0c3q87fLL9Xm69X68tOmUrVocqU0b_uh56IZOmUYZxQ06bUmQBo21KzTINpRKUbrkoxWjVCc9hxgGHvgteLn6ONB924_TEYrU74GTt5FO0H8IQNY-e_G21u5DfeS8VZQQYrA8iCgYkgpmvEPlxI5dyTnjuTckZw7KoR3fzs-w4-lFMD7IwBSyWMsGSmbnnE15ZzSWejigEtl5bcmyl3Yx9JD-p_1b9Q7rgo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Atzpodien, J ; Kirchner, H ; Illiger, H J ; Metzner, B ; Ukena, D ; Schott, H ; Funke, P J ; Gramatzki, M ; Jürgenson, S von ; Wandert, T ; Patzelt, T ; Reitz, M</creator><creatorcontrib>Atzpodien, J ; Kirchner, H ; Illiger, H J ; Metzner, B ; Ukena, D ; Schott, H ; Funke, P J ; Gramatzki, M ; Jürgenson, S von ; Wandert, T ; Patzelt, T ; Reitz, M ; D. G. C. I. N. (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group)</creatorcontrib><description>We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-α2a, subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients with progressive metastatic renal cell carcinoma. Treatment courses consisted of interferon-α2a 5 × 10
6
IU m
–2
day 1 weeks 1 + 4; days 1, 3, 5 weeks 2 + 3; 10 × 10
6
IU m
–2
days 1, 3, 5 weeks 5–8; interleukin-2 10 × 10
6
IU m
–2
twice daily days 3–5 weeks 1 + 4; 5 × 10
6
IU m
–2
days 1, 3, 5 weeks 2 + 3; and 5-fluorouracil 1000 mg m
–2
day 1 weeks 5–8. The tamoxifen group received tamoxifen 80 mg twice daily over 8 weeks. Among 41 patients treated with interleukin-2, interferon-α2a and 5-fluorouracil there were 7 complete (17.1%) and 9 partial responders (21.9%), with an overall objective response rate of 39.1% (95% CI, 24.2–55.5). An additional 15 patients (36.6%) were stable throughout therapy. The overall survival was 24 months (range 5–76+). In 37 patients receiving tamoxifen no objective remissions occurred. 13 patients (35.1%) had stable disease and 24 patients (64.9%) showed continued disease progression. The overall survival was 13 months (range 3–73+). In summary, this home-based therapy regimen of interferon-α2a, interleukin-2 and 5-fluorouracil demonstrated significant therapeutic efficacy in patients with progressive renal cell carcinoma when compared to hormonal therapy. © 2001 Cancer Research Campaign
http://www.bjcancer.com</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1054/bjoc.2001.2076</identifier><identifier>PMID: 11710825</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - mortality ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Drug Resistance ; Epidemiology ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - adverse effects ; Humans ; Interferon-alpha - administration & dosage ; Interferon-alpha - adverse effects ; Interleukin-2 - administration & dosage ; Interleukin-2 - adverse effects ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - mortality ; Male ; Medical sciences ; Middle Aged ; Molecular Medicine ; Neoplasm Metastasis ; Oncology ; Pharmacology. Drug treatments ; Prospective Studies ; Regular ; regular-article ; Tamoxifen - adverse effects ; Tamoxifen - therapeutic use</subject><ispartof>British journal of cancer, 2001-10, Vol.85 (8), p.1130-1136</ispartof><rights>The Author(s) 2001</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.</rights><rights>Copyright © 2001 Cancer Research Campaign 2001 Cancer Research Campaign</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-cd379b9356b8ce2321ad09dd0a062b428da57fcc214153dc65c3193aabf9a34c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375150/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375150/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14133116$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11710825$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Atzpodien, J</creatorcontrib><creatorcontrib>Kirchner, H</creatorcontrib><creatorcontrib>Illiger, H J</creatorcontrib><creatorcontrib>Metzner, B</creatorcontrib><creatorcontrib>Ukena, D</creatorcontrib><creatorcontrib>Schott, H</creatorcontrib><creatorcontrib>Funke, P J</creatorcontrib><creatorcontrib>Gramatzki, M</creatorcontrib><creatorcontrib>Jürgenson, S von</creatorcontrib><creatorcontrib>Wandert, T</creatorcontrib><creatorcontrib>Patzelt, T</creatorcontrib><creatorcontrib>Reitz, M</creatorcontrib><creatorcontrib>D. G. C. I. N. (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group)</creatorcontrib><title>IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-α2a, subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients with progressive metastatic renal cell carcinoma. Treatment courses consisted of interferon-α2a 5 × 10
6
IU m
–2
day 1 weeks 1 + 4; days 1, 3, 5 weeks 2 + 3; 10 × 10
6
IU m
–2
days 1, 3, 5 weeks 5–8; interleukin-2 10 × 10
6
IU m
–2
twice daily days 3–5 weeks 1 + 4; 5 × 10
6
IU m
–2
days 1, 3, 5 weeks 2 + 3; and 5-fluorouracil 1000 mg m
–2
day 1 weeks 5–8. The tamoxifen group received tamoxifen 80 mg twice daily over 8 weeks. Among 41 patients treated with interleukin-2, interferon-α2a and 5-fluorouracil there were 7 complete (17.1%) and 9 partial responders (21.9%), with an overall objective response rate of 39.1% (95% CI, 24.2–55.5). An additional 15 patients (36.6%) were stable throughout therapy. The overall survival was 24 months (range 5–76+). In 37 patients receiving tamoxifen no objective remissions occurred. 13 patients (35.1%) had stable disease and 24 patients (64.9%) showed continued disease progression. The overall survival was 13 months (range 3–73+). In summary, this home-based therapy regimen of interferon-α2a, interleukin-2 and 5-fluorouracil demonstrated significant therapeutic efficacy in patients with progressive renal cell carcinoma when compared to hormonal therapy. © 2001 Cancer Research Campaign
http://www.bjcancer.com</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - mortality</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - adverse effects</subject><subject>Humans</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - adverse effects</subject><subject>Interleukin-2 - administration & dosage</subject><subject>Interleukin-2 - adverse effects</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - mortality</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Neoplasm Metastasis</subject><subject>Oncology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Regular</subject><subject>regular-article</subject><subject>Tamoxifen - adverse effects</subject><subject>Tamoxifen - therapeutic use</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp1UctuEzEUtRAVTQtblsgblpP6MZ4HCyRUkRIpKhu6tu7YntSRx65spwW-pL_RH-Gb8CgRhQWba1v3PKxzEHpLyZISUV8Mu6CWjBBaRtu8QAsqOKtox9qXaEEIaSvSM3KKzlLalWdPuvYVOqW0paRjYoEe15uKYeuxCtNgPWQbPH6w-RavV9fVryfwGotqdYPvTUz7hDNM4bsdjZ85k8mQcuEoHI0Hh5VxZUBU1ocJPmAX_LbKJk5ln_YuJxxGDMXL5xicMxrHYhAm-7NclbPeqqKSowX3Gp2M4JJ5czzP0c3q87fLL9Xm69X68tOmUrVocqU0b_uh56IZOmUYZxQ06bUmQBo21KzTINpRKUbrkoxWjVCc9hxgGHvgteLn6ONB924_TEYrU74GTt5FO0H8IQNY-e_G21u5DfeS8VZQQYrA8iCgYkgpmvEPlxI5dyTnjuTckZw7KoR3fzs-w4-lFMD7IwBSyWMsGSmbnnE15ZzSWejigEtl5bcmyl3Yx9JD-p_1b9Q7rgo</recordid><startdate>20011019</startdate><enddate>20011019</enddate><creator>Atzpodien, J</creator><creator>Kirchner, H</creator><creator>Illiger, H J</creator><creator>Metzner, B</creator><creator>Ukena, D</creator><creator>Schott, H</creator><creator>Funke, P J</creator><creator>Gramatzki, M</creator><creator>Jürgenson, S von</creator><creator>Wandert, T</creator><creator>Patzelt, T</creator><creator>Reitz, M</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20011019</creationdate><title>IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial</title><author>Atzpodien, J ; Kirchner, H ; Illiger, H J ; Metzner, B ; Ukena, D ; Schott, H ; Funke, P J ; Gramatzki, M ; Jürgenson, S von ; Wandert, T ; Patzelt, T ; Reitz, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-cd379b9356b8ce2321ad09dd0a062b428da57fcc214153dc65c3193aabf9a34c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - mortality</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - adverse effects</topic><topic>Humans</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - adverse effects</topic><topic>Interleukin-2 - administration & dosage</topic><topic>Interleukin-2 - adverse effects</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - mortality</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Neoplasm Metastasis</topic><topic>Oncology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Regular</topic><topic>regular-article</topic><topic>Tamoxifen - adverse effects</topic><topic>Tamoxifen - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Atzpodien, J</creatorcontrib><creatorcontrib>Kirchner, H</creatorcontrib><creatorcontrib>Illiger, H J</creatorcontrib><creatorcontrib>Metzner, B</creatorcontrib><creatorcontrib>Ukena, D</creatorcontrib><creatorcontrib>Schott, H</creatorcontrib><creatorcontrib>Funke, P J</creatorcontrib><creatorcontrib>Gramatzki, M</creatorcontrib><creatorcontrib>Jürgenson, S von</creatorcontrib><creatorcontrib>Wandert, T</creatorcontrib><creatorcontrib>Patzelt, T</creatorcontrib><creatorcontrib>Reitz, M</creatorcontrib><creatorcontrib>D. G. C. I. N. (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group)</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Atzpodien, J</au><au>Kirchner, H</au><au>Illiger, H J</au><au>Metzner, B</au><au>Ukena, D</au><au>Schott, H</au><au>Funke, P J</au><au>Gramatzki, M</au><au>Jürgenson, S von</au><au>Wandert, T</au><au>Patzelt, T</au><au>Reitz, M</au><aucorp>D. G. C. I. N. (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2001-10-19</date><risdate>2001</risdate><volume>85</volume><issue>8</issue><spage>1130</spage><epage>1136</epage><pages>1130-1136</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-α2a, subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients with progressive metastatic renal cell carcinoma. Treatment courses consisted of interferon-α2a 5 × 10
6
IU m
–2
day 1 weeks 1 + 4; days 1, 3, 5 weeks 2 + 3; 10 × 10
6
IU m
–2
days 1, 3, 5 weeks 5–8; interleukin-2 10 × 10
6
IU m
–2
twice daily days 3–5 weeks 1 + 4; 5 × 10
6
IU m
–2
days 1, 3, 5 weeks 2 + 3; and 5-fluorouracil 1000 mg m
–2
day 1 weeks 5–8. The tamoxifen group received tamoxifen 80 mg twice daily over 8 weeks. Among 41 patients treated with interleukin-2, interferon-α2a and 5-fluorouracil there were 7 complete (17.1%) and 9 partial responders (21.9%), with an overall objective response rate of 39.1% (95% CI, 24.2–55.5). An additional 15 patients (36.6%) were stable throughout therapy. The overall survival was 24 months (range 5–76+). In 37 patients receiving tamoxifen no objective remissions occurred. 13 patients (35.1%) had stable disease and 24 patients (64.9%) showed continued disease progression. The overall survival was 13 months (range 3–73+). In summary, this home-based therapy regimen of interferon-α2a, interleukin-2 and 5-fluorouracil demonstrated significant therapeutic efficacy in patients with progressive renal cell carcinoma when compared to hormonal therapy. © 2001 Cancer Research Campaign
http://www.bjcancer.com</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>11710825</pmid><doi>10.1054/bjoc.2001.2076</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2001-10, Vol.85 (8), p.1130-1136 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2375150 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature Journals Online; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - mortality Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Drug Resistance Epidemiology Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Interleukin-2 - administration & dosage Interleukin-2 - adverse effects Kidney Neoplasms - drug therapy Kidney Neoplasms - mortality Male Medical sciences Middle Aged Molecular Medicine Neoplasm Metastasis Oncology Pharmacology. Drug treatments Prospective Studies Regular regular-article Tamoxifen - adverse effects Tamoxifen - therapeutic use |
| title | IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A51%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=IL-2%20in%20combination%20with%20IFN-%CE%B1and%205-FU%20versus%20tamoxifen%20in%20metastatic%20renal%20cell%20carcinoma:%20long-term%20results%20of%20a%20controlled%20randomized%20clinical%20trial&rft.jtitle=British%20journal%20of%20cancer&rft.au=Atzpodien,%20J&rft.aucorp=D.%20G.%20C.%20I.%20N.%20(German%20Cooperative%20Renal%20Carcinoma%20Chemo-Immunotherapy%20Trials%20Group)&rft.date=2001-10-19&rft.volume=85&rft.issue=8&rft.spage=1130&rft.epage=1136&rft.pages=1130-1136&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1054/bjoc.2001.2076&rft_dat=%3Cpubmed_cross%3E11710825%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11710825&rfr_iscdi=true |